To the Editor: Dr Eklind-Cervenka and colleagues provided a retrospective analysis of the Swedish Heart Failure Registry showing a survival benefit of candesartan over losartan in patients with heart failure (HF) at 1 and 5 years.1 The association of lower mortality with candesartan was found both in patients with depressed (<40%) and preserved (≥40%) left ventricular ejection fraction. Although the authors offered various explanations for this benefit, they did not mention that losartan has never shown a benefit over any other angiotensin II–receptor blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor in HF patients.
Fruhwald F, Pieske B. Candesartan vs Losartan and Mortality in Patients With Heart Failure. JAMA. 2011;305(15):1540–1542. doi:10.1001/jama.2011.462
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: